Core Viewpoint - The weight loss drug sector is experiencing significant fluctuations, with several companies seeing substantial stock price increases [1] Company Summary - Boji Pharmaceutical (300404) and Ganli Pharmaceutical (603087) have reached their daily price limit increase [1] - Aorite (605116), Deyuan Pharmaceutical, and Meinuohua (603538) are also witnessing stock price increases, indicating a broader trend in the sector [1]

Group 1 - The A-share market saw a significant rise in pharmaceutical stocks, with notable performances including Furuide Co., Ltd. hitting a 20% limit up, and Boji Pharmaceutical rising by 14% [1] - Other companies such as Jimin Health and Kangyuan Pharmaceutical also experienced substantial gains, with both reaching a 10% limit up [1] - The overall trend indicates a bullish sentiment in the pharmaceutical sector, with multiple stocks showing increases of over 5% [1] Group 2 - Furuide Co., Ltd. reported a market capitalization of 19.1 billion and a year-to-date increase of 129.01% [2] - Boji Pharmaceutical had a market cap of 4.819 billion and a year-to-date increase of 43.33% [2] - Other notable companies include Jimin Health with a market cap of 5.66 billion and a year-to-date increase of 58.76%, and Kangyuan Pharmaceutical with a market cap of 11.2 billion and a year-to-date increase of 45.59% [2]

博济医药最新一期业绩显示，截至2025一季报，公司营业总收入1.39亿元、同比减少17.06%，归属净利 润390.06万元，同比减少76.38%，扣非净利润169.79万元，同比减少88.28%，流动比率1.935、速动比率 1.418、资产负债率31.99%。 金融界消息 截至2025年8月15日收盘，博济医药（300404）报收于10.92元，上涨0.92%，换手率6.2%， 成交量17.41万手，成交金额1.89亿元。 资金流向方面，今日主力资金净流出1386.75万元，占比成交额7.32%。其中，超大单净流入116.66万 元、占成交额0.62%，大单净流出1503.41万元、占成交额7.94%，中单净流出流出192.13万元、占成交 额1.01%，小单净流入1578.88万元、占成交额8.33%。 来源：金融界 天眼查商业履历信息显示，博济医药科技股份有限公司，成立于2002年，位于广州市，是一家以从事研 究和试验发展为主的企业。企业注册资本38198.9708万人民币，实缴资本10000万人民币。公司法定代 表人为王廷春。 通过天眼查大数据分析，博济医药科技股份有限公司共对外投资了39家企业，参 ...

Group 1 - The company, Boji Pharmaceutical, primarily focuses on the research and development of chemical drugs, with significant capabilities in liver disease, digestive disorders, tumors, and endocrine research services [1] - The company also provides services related to traditional Chinese medicine, biological drugs, and medical devices, but chemical drug development is the main area of expertise [1] - There is currently no authoritative statistical data available regarding the market share of the company's services [1]

Group 1 - The company Boji Pharmaceutical has received approval for its tadalafil tablets in 5mg, 10mg, and 20mg dosages [1] - The approved tadalafil products are marketed under the brands "Gun Ge" and "Weil Chang" [1]

（文章来源：证券日报） 证券日报网讯博济医药8月13日在互动平台回答投资者提问时表示，公司通过在国外成立子公司，组建 国外业务部门，引入有国际业务经验的人才，积极拓展国外临床业务。 ...

证券日报网讯博济医药8月13日在互动平台回答投资者提问时表示，公司控股子公司九泰药械是一家专 注于医疗器械第三方外包服务的CRO公司，主要为客户提供医疗器械相关的临床试验以及注册申报服 务，目前暂无脑机接口领域相关的项目。九泰药械积极关注脑机接口相关领域，也有能力为脑机接口医 疗器械的注册及临床试验提供全流程服务。 （文章来源：证券日报） ...

格隆汇8月13日丨博济医药(300404.SZ)在互动平台表示，公司控股子公司九泰药械是一家专注于医疗器 械第三方外包服务的CRO公司，主要为客户提供医疗器械相关的临床试验以及注册申报服务，目前暂 无脑机接口领域相关的项目。九泰药械积极关注脑机接口相关领域，也有能力为脑机接口医疗器械的注 册及临床试验提供全流程服务。 ...

格隆汇8月13日丨博济医药(300404.SZ)在互动平台表示，公司控股子公司九泰药械是一家专注于医疗器 械第三方外包服务的CRO公司，主要为客户提供医疗器械相关的临床试验以及注册申报服务，目前暂 无脑机接口领域相关的项目。九泰药械积极关注脑机接口相关领域，也有能力为脑机接口医疗器械的注 册及临床试验提供全流程服务。 ...

公司回答表示：您好，公司通过在国外成立子公司，组建国外业务部门，引入有国际业务经验的人才， 积极拓展国外临床业务。感谢您的关注！ 金融界8月13日消息，有投资者在互动平台向博济医药提问：公司有没有在积极拓展国外市场？ ...